Horizon Discovery raises $18.6M, plots IPO; Theravance wins European OK for Vibativ; NABsys banks $10M;

@FierceBiotech: FDA approves test to determine chances of ovarian cancer. Piece | Follow @FierceBiotech

@JohnCFierce: Soligenix will now look at cost containment measures now that orBec Ph3 is a bust. Here's the PR: Item | Follow @JohnCFierce

@RyanMFierce: Neat. Computer-based therapy for anxiety may be as effective as seeing a therapist or taking drugs. Brown U.'s release: Release | Follow @RyanMFierce

@MaureenFierce: 'Contagion' plausible, but not for vaccine development. Story | Follow @MaureenFierce

> The U.K.'s Horizon Discovery has rounded up $18.6 million in a new venture round as it moves beyond an initial focus on cancer drugs. Horizon is reportedly planning to beef up its staff and lay the foundation for an IPO. Story

> Astellas and Theravance won European approval for Vibativ (telavancin hydrochloride), an injectable antibacterial that guards against Gram-positive bacteria, such as MRSA. Release

>  The DNA sequencing company NABsys has raised $10 million in new venture funds. The Series C was led by Stata Venture Partners and brings its venture take to $21 million. NABsys release

> Abbott Laboratories is cutting 10 HQ staffers and about 150 manufacturing jobs in Santa Clara, CA. Report

Pharma News

@FiercePharma: FDA expects another foreign-drug safety crisis a la heparin... if it doesn't get more enforcement powers. Story | Follow @FiercePharma

> CEO: Novartis cost cuts to target sales, manufacturing. Article

> J&J's Scios to plead guilty, pay $85M in Natrecor case. News

> Australia's iNova may go on block for $718M-plus. Item

> Watson, Sandoz settle Medicaid whistleblower suits for $145M. Report

> GSK looks to McLaren for help shifting to higher gear. More

> Foreign-made drug crisis coming, FDA tells Congress. Piece

Vaccines News

> FDA lifts clinical hold on RXi's breast cancer vaccine. News

> Bionor HIV vaccine lowers viral load, ART need. Story

> Researchers find weakness in hep C virus. Report

> Medicago unveils new NC manufacturing plant. Article

> Study: For HPV, two shots may be enough. News

Manufacturing News

> Daiichi riding GMP rollercoaster with FDA. Report

> Teva gets close-out letter over Jerusalem plant. Story

> Competition forcing marriage of iPads, ops data for execs. Article

> Seattle the exception in hosting medical marijuana dispensaries. Report

> Catalent expansions show close pharma-biz tracking. News

And Finally... Researchers at Cornell say they've solved the age-old puzzle of breaching the blood-brain barrier, allowing for better drug delivery. Release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.